An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma - Regional Cancer Care Associates LLC

Clinical Trials

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma
Locations
Bethesda
Sponsor
Bristol Myers-Squibb
Protocol Number
CA209602
Cancer Diagnosis
To Learn More Call
201-510-0910